Myeloma Crowd published a post a few days ago about the impact and importance of adequate Vitamin D levels on the survival statistics of myeloma patients. We would like to add to that today with the pre-print publication of a research study that studied links between Vitamin D deficiencies and COVID-19 severity and mortality. Let’s first explain what a pre-print article is. Pre-print means that the article in question has not yet been peer reviewed for journal publication. Still, in this case the article in question was (a) published by a well-known, well-established, credible organization (Northwestern University, Illinois, USA); and (b) was co-authored by a well-established researcher (Vadim Backman, Walter Dill Scott Professor of Biomedical Engineering at Northwestern's McCormick School of Engineering).
The research in question is not specifically related to myeloma and/or myeloma treatment, but we feel that is important for myeloma patients to be aware of, especially in light of the Myeloma Crowd post referenced above. Let me give you two links to refer to :
‘Backman and his team were inspired to examine vitamin D levels after noticing unexplained differences in COVID-19 mortality rates from country to country. Some people hypothesized that differences in healthcare quality, age distributions in population, testing rates or different strains of the coronavirus might be responsible. But Backman remained skeptical. "None of these factors appears to play a significant role," Backman said. "The healthcare system in northern Italy is one of the best in the world. Differences in mortality exist even if one looks across the same age group. And, while the restrictions on testing do indeed vary, the disparities in mortality still exist even when we looked at countries or populations for which similar testing rates apply. "Instead, we saw a significant correlation with vitamin D deficiency," he said.’
The research team studied data from a large group of patients from 10 different countries, each with large numbers of Covid-19 patients. You will learn about C-reactive proteins (CRP), that ‘are produced by the liver in response to inflammation to minimize damage to arteries, cells, and tissue from autoimmunity, infection, and other causes. The inflammatory cells’ ability to convert Vit D metabolites into calcitriol (the active form of Vit D) … suggests a potential inverse association between CRP and Vit D.’ Or to put it simply : for a patient, having high levels of CRP is not a good thing and there is a relationship between low levels of Vitamin D and high levels of CRP.
The study resulted in several interesting observations :
The authors caution that more research needs to be done, In specific, they recommend a double blind study that uses specific patient data to quantify the more exact relationship between Vitamin-D levels and severity (and mortality) of COVID-10 patients that does not rely on the population data bases from the 10 countries their current data set.
What does it all mean for the myeloma patient ? A few days ago, we learned that Vitamin D deficiency has an adverse effect on us. Now we learn that Vitamin D sufficiency will not protect us from COVID-19 infection, but it may well lessen the clinical severity of the infection, especially for the older ones among us.
about the author
I am a patient diagnosed in 2014 with primary plasma cell leukemia (pPCL), a rare and aggressive variant of multiple myeloma and have been very fortunate to find successful treatment at the division of Cellular Therapy at the Duke University Cancer Institute. My wife, Vicki, and I have two adult children and two grandsons who are the ‘lights of our lives’. Successful treatment has allowed Vicki and I to do what we love best : traveling the world, albeit it with some extra precautions to keep infections away. My career in the pharmaceutical industry has given me insights that I am currently putting to use as an advocate to lower drug pricing, especially prices for anti-cancer drugs. I am a firm believer that staying mentally active, physically fit, compliant to our treatment regimen and taking an active interest in our disease are keys to successful treatment outcomes.